Mirabegron Powder
NDC Package 76072-1013-1
Package Information
Mirabegron powders is a medication used to treat overactive bladder. This formulation utilizes a powder delivery system. Marketed by Cohance Lifesciences Limited, this product is identified by NDC 76072-1013.
Identification & Billing
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 76072 - Cohance Lifesciences Limited
- 76072-1013 -
- 76072-1013-1 - 25 kg in 1 DRUM
- 76072-1013 -
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 76072-1013-1 identifies a specific commercial package of 25 kg in 1 drum of Mirabegron (UNFINISHED drug), a bulk ingredient labeled by Cohance Lifesciences Limited. This powder is formulated for use and contains mirabegron as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Cohance Lifesciences Limited on March 27, 2018. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat overactive bladder. Overactive bladder is a problem with how your bladder stores urine that causes a sudden urge to urinate. The urge may be hard to control, and overactive bladder symptoms may include frequent urination, strong sudden urges to urinate, or involuntary loss of urine (incontinence). Mirabegron works by relaxing a certain bladder muscle (detrusor), which helps the bladder hold more urine and lessens symptoms of overactive bladder.
How is this Cohance Lifesciences Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 76072101301. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.